Combining selinexor with alisertib to target the p53 pathway in neuroblastoma

Neuroblastoma accounts for 15% of cancer-related deaths in children, highlighting an unmet need for novel therapies. Selinexor is a small molecule inhibitor of XPO1. XPO1 shuffles cargo proteins with a nuclear export sequence from the nucleus to the cytosol, many of which are essential for cancer gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Rosa, Wang, Hong, Sun, Ming, Lee, Dong Geun, Peng, Junmin, Thiele, Carol J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866064/
https://www.ncbi.nlm.nih.gov/pubmed/35217309
http://dx.doi.org/10.1016/j.neo.2022.100776

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866064/
https://www.ncbi.nlm.nih.gov/pubmed/35217309
http://dx.doi.org/10.1016/j.neo.2022.100776

Ejemplares similares